Company at a Glance
Virility Medical is a privately held Israeli medical device start-up company, committed to the development of climax control of premature ejaculation. The company is in advanced clinical stage, developing an intimate skin patch with neuromodulation capabilities.
Premature ejaculation is the most common sexual dysfunction in men. Existing treatments for premature ejaculation relay mostly on pharmacotherapy. Oral therapies include antidepressant drugs, which are mainly prescribed off-label. These drugs have limited efficacy and are associated with systemic side effects, such as headaches and nausea, as well as sexual side effects, such as diminished libido and decreased fertility. Another alternative is topical therapy, i.e. the application of desensitizing agents. This treatment method also offers limited efficacy, along with side effects such as diminished spontaneity and transvaginal absorption resulting in vaginal numbness.
There is still no effective treatment for premature ejaculation.
The premature ejaculation market is expected to grow at a Compound Annual Growth Rate (CAGR) of 9.65% and reach $1.95B by 2020. It is estimated that approx. 79 million men are suffering from premature ejaculation in the US and EU, where more than 15 million men are actively seeking medical solution (based on a study performed by Frost & Sullivan).
Virility has successfully completed two clinical studies, and planning to submit for CE by the end of 2017.
Technology & Product(s)
Virility is developing a perineal skin patch for climax control of premature ejaculation. The patch carries an electronic module which delivers low intensity transcutaneous electrical stimulation to the adjacent nerves and muscles.
The patch is flexible and easily conforms to local anatomy. It can be applied even hours before intercourse and allows to maintain sexual spontaneity.
Ejaculation is delayed by electrically inhibiting the typical rhythmic contractions of the muscle responsible for ejaculation.
The patch is fully controlled by a mobile app, allowing the user to precisely determine the intensity of the stimulation.
After climax, as the muscle regains its typical functionality, the patch can be removed and disposed of.
The patch does not use any drugs or needles. It affects only the targeted muscles and only for the duration of intercourse.
The product is planned to be sold Over the Counter.
Objectives: Allow distributors to touch and feel the product, product exposure and rising awareness, identifying distribution channels and partners.
Target businesses: Distributors, pharmacies and retail companies.
Target Countries: EU, US, Canada, China, Japan.